Skip to main content

About this Research Topic

Submission closed.

In the last decade, significant technical development has been achieved providing wide range of availability of LINAC-based radiosurgery. Several clinical trials prove the advantage of stereotactic radiotherapy (stereotactic ablative radiotherapy (SABR) Stereotactic body radiotherapy (SBRT), fractionated ...

In the last decade, significant technical development has been achieved providing wide range of availability of LINAC-based radiosurgery. Several clinical trials prove the advantage of stereotactic radiotherapy (stereotactic ablative radiotherapy (SABR) Stereotactic body radiotherapy (SBRT), fractionated stereotactic radiosurgery, and radiotherapy (fSRS, SRT) of single and oligometastatic cancers in different locations. (COMET 1, COMET2, STAMPEDE, NHS England Commissioning through Evaluation scheme, SINDAS). Recent research on novel imaging, such as PSMA PET/CT, 4DCT/PETCT, and advanced sequences of MRI, provides superior accuracy for target definition and target motion management. Fractionated SBRT, SRS, and SRT delivery enable the use of adaptive radiation approaches. Optimization of the standard operating procedures of stereotactic radiotherapy may result in improvement of the effectivity and the therapeutic index.

This Research Topic aims to collect studies to update and discuss the recent advances in stereotactic radiotherapy addressing important technical and clinical questions on LINAC-based hypofractionated high dose delivery for the treatment of oligometastatic disease. Indication, treatment preparation including advanced imaging for target definition of SBRT, SRT for diverse cancer types such as prostate, lung, breast, kidney, liver, pancreatic malignancies, and less frequent tumors such as melanoma, sarcoma could be studied in different clinical situations like early-stage cancer, oligo-site progression and local recurrence in pretreated location. Optimization of treatment delivery (time and volume determination, on-board and repeated imaging, target motion monitoring, and management) can be evaluated along with outcome results.

We welcome submissions on, but not limited to, the following themes:
- Positioning, immobilization, and target motion detection in the preparatory phase of SABR, SRS
- Use of advanced imaging for target definition, and motion follow up
- Fractionation, timing, and dosage of radiation
- Radiation delivery and imaging techniques, quality assurance
- Evaluation of the treatment outcome in correlation to the clinical factors and radiation parameters

Original Research, in the above-listed topics, is preferred as the manuscript type.

Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.

Keywords: SRT, brain metastases, Lung cancer, Metastatic llung cancer, Prostate cancer, Melanoma malignum, oligometastatic disease, stereotactic ablative body radiotherapy (SABR), stereotactic body radiation therapy (SBRT)


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Topic Editors

Loading..

Topic Coordinators

Loading..

Recent Articles

Loading..

Articles

Sort by:

Loading..

Authors

Loading..

total views

total views article views downloads topic views

}
 
Top countries
Top referring sites
Loading..

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.